You are here:
Early stage

High-risk molecules

Safety first

At Kendle, safety is our number one priority and nowhere is this more important than in our First-in-Human studies. Novel biopharmaceutical entities are now targeting biochemical pathways that are not yet fully elucidated. To help you monitor these effects in the safest and most highly controlled environment, we have our own dedicated research center located on the campus of the University Medical Center, Utrecht in The Netherlands.

Exceeding the standard

We try our utmost to mitigate any unnecessary risks, ensuring the safety of our volunteers and investigational personnel at all times. This is accomplished through our industry-leading medical expertise, around-the-clock monitoring and our state-of-the-art equipment and medical facilities.

Click here to download our high-risk molecules fact sheet

Read more about our early stage expertise